Clinical Trial

A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

Study acronym: MICA
Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated November 24, 2025 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
CLN-619-001 is a Phase 1, open-label, multi-center study of CLN-619 alone and in combination with pembrolizumab in patients with advanced solid tumors.
Protocol Amendment History 16 amendments
This ClinicalTrials.gov record has been amended 16 times since 2021-11-02; most recent amendment 2025-11-19.
Status change: Recruiting → Active, Not Recruiting 2025-11-19
Trial Details
NCT Number NCT05117476
Lead Sponsor Cullinan Therapeutics Inc.
Conditions Advanced Solid Tumor, NSCLC
Enrollment 440 participants
Start Date 2021-10-29
Primary Completion 2026-03 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2025-11-24